Skip to main content
. 2021 Sep 27;13(19):4831. doi: 10.3390/cancers13194831

Figure 6.

Figure 6

Exploiting VRAC expression levels as a strategy for personalized medicine in HNSCC. While tumors expressing high VRAC levels (green) are likely to be killed by cisplatin therapy, low VRAC levels may signal the development of resistance and thus may indicate the need for alternative treatment strategies. VRAC-based patient stratification could improve success rates in first-line chemotherapy.